MBRX

Moleculin Biotech, Inc. (MBRX) Business Model Analysis (2026)

Invetso Score: 2.6/10 — Weak · Last Updated: 2026-09-01

Overall Score

Revenue Quality

No revenue is reported in the TTM data, so the business model is not yet demonstrating commercial scale.

Gross, operating, EBITDA, and net margins are all 0%, indicating no evidence of profitable revenue generation.

Profitability

TTM returns are deeply negative, including ROA of -1.44%, ROE of -8.17%, and ROIC of -2.42%.

Operating return on assets is -1.30% and return on tangible assets is -3.05%, showing the asset base is not producing earnings.

Cash Flow

Operating cash flow and free cash flow are both negative on a per-share basis, with free cash flow per share at -4.46.

Cash flow coverage metrics are extremely weak, reflecting continued cash burn and limited internal funding capacity.

Balance Sheet

The company has low reported debt relative to capital, with debt-to-capital at 2.46% and debt-to-assets at 1.38%.

Liquidity is tight, as the current ratio is 0.94 and working capital is negative at -$0.59M, but cash per share of $1.28 provides some near-term cushion.

Capital Efficiency

Capital efficiency remains poor, with return on invested capital at -2.42% and return on capital employed at -2.45%.

Asset turnover is 0 and working capital turnover is 0, indicating the asset base is not being used to generate sales.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Moleculin Biotech, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →